Pharmacogenomics--practice and challenges.
Aust Fam Physician. 2010 Oct;39(10):788-90
Authors: Ghosh R, Ghosh S, Chawla S
Generating revenue of over $1 billion annually to owner companies, blockbuster drugs have been a prominent feature of drug development over recent decades. However, a large number of patients have an inadequate therapeutic response to the 'one size fits all' blockbuster drugs. It is difficult to predict which patient subgroups will respond well to a drug and which will have significant adverse reactions.
PMID: 20890484 [PubMed - indexed for MEDLINE]